Italia markets close in 8 hours 23 minutes

BioAtla, Inc. (BCAB)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,4700+0,0600 (+4,26%)
Alla chiusura: 04:00PM EDT
1,4300 -0,04 (-2,72%)
Dopo ore: 05:53PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

    Award recognizes Dr. Short’s contribution to science innovationSAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and Cofounder, has been chosen by The Explorers Club as a recipient of this year’s Lowell Thomas Award. Dr. Short’s a

  • GlobeNewswire

    BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

    Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conferenceR&D day planned for December 13, 2023, to discuss BA3071 (CAB-CTLA-4) Phase 1/2 basket trialManagement to host third quarter 2023 financial results conference call and webcast on Tuesday, November 7, 2023 at 4:30 PM Eastern Time SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Bi

  • GlobeNewswire

    BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

    SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023. Format: Fi